News - Oncology

Filter

Current filters:

Oncology

Popular Filters

151 to 175 of 1469 results

Heron Therapeutics says timeline for Sustol resubmission delayed

28-01-2014

US specialty pharma group Heron Therapeutics saw its shares plunge after the company revealed an around…

Heron TherapeuticsNorth AmericaOncologyPharmaceuticalRegulationSustolUSA

Ariad Pharma plans commercialization of Iclusig in Australia

Ariad Pharma plans commercialization of Iclusig in Australia

28-01-2014

US specialty pharma firm Ariad Pharmaceuticals has signed an agreement with Specialised Therapeutics…

Ariad PharmaceuticalsAsia-PacificAustraliaIclusigLicensingOncologyPharmaceuticalSpecialised Therapeutics Australia

Curie-Cancer and Servier renew partnership into ‘triple negative’ breast cancers

Curie-Cancer and Servier renew partnership into ‘triple negative’ breast cancers

28-01-2014

French privately-held drugmaker Servier has renewed its partnership with Curie-Cancer to identify therapeutic…

FranceOncologyPharmaceuticalResearchServier

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

28-01-2014

US pharma giant Pfizer has released disappointing top-line results from two randomized Phase III studies…

dacomitinibOncologyPfizerPharmaceuticalResearch

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

28-01-2014

UK drugs watchdog the National Institute of Health and Care Excellence (NICE) has issued new draft guidance…

Astellas PharmaEuropeOncologyPharmaceuticalPricingRegulationUKXtandi

Celsion’s ThermoDox in combination treatment improves survival by more than 50%

27-01-2014

US cancer drug developer Celsion Corp (Nasdaq: CLSN) says that the latest overall survival data from…

CelsionOncologyPharmaceuticalResearchThermoDoxUSA

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

27-01-2014

UK pharma major GlaxoSmithKline announced that its Phase III study of the combination of Tafinlar (dabrafenib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalResearchTafinlarUK

Medigene acquires Trianta Immunotherapies

27-01-2014

Germany’s Medigene this morning revealed that it has acquired 100% of the shares of the Munich-based…

MedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesVaccines

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

22-01-2014

The bladder cancer therapeutics market in the six major countries is forecast to climb from $239.3 million…

EOquinEuropeMarkets & MarketingOncologyPharmaceuticalSpectrum PharmaceuticalsUSA

Patrys shares rise as 10-year data shows PAT-SC1 improves survival

22-01-2014

Australian biotech company Patrys (ASX: PAB) has published 10-year follow up data for its product PAT-SC1…

AustraliaBiotechnologyOncologyPAT-SC1PatrysResearch

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

22-01-2014

An innovative screening technology that tags compounds with unique strands of DNA will be used to assess…

BiotechnologyDenmarkNuevolutionOncologyResearchUK

Hybrigenics achieves research milestone under Servier collaboration

Hybrigenics achieves research milestone under Servier collaboration

21-01-2014

French drug developer Hybrigenics says it has achieved first drug discovery milestone in connection with…

FinancialHybrigenicsOncologyPharmaceuticalResearchServier

Norgine and Kissei’s Savene approved in Japan

21-01-2014

Independent Dutch firm Norgine and its Japanese partner Kissei Pharmaceutical received approval from…

Asia-PacificKissei PharmaceuticalNorgineOncologyPharmaceuticalRegulationSavene

Biocon introduces biosimilar trastuzumab for breast cancer in India

20-01-2014

India-based biotech firm Biocon (BSE: 532523) has introduced Canmab, a biosimilar trastuzumab, for the…

BioconBiosimilarsIndiaMarkets & MarketingOncologytrastuzumab

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

18-01-2014

US biotech firm Celgene’s breast cancer drug, Abraxane (nanoparticle albumin-bound paclitaxel), has…

AbraxaneBiotechnologyCelgeneOncologyResearchSpecialised Therapeutics Australia

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

151 to 175 of 1469 results

Back to top